Your list points out something important:
Despite the biotech indexes apparently running up near March highs in some cases, the fact still remains that approx 1/2 of all biotechs trade substantially off their 52 week lows.
It makes more sense to me to enter at a point where the downsides for the most part have been taken out.
CRA, INCY, AFFX - most are still relatively cheap. Good basic picks and shovel group. RSTA good company but has just about doubled since I bought it last month on the post-ipo dip.
IMCL now getting expensive, real cheap last month
CEGE still cheap, although starting to move up. Its large ABGX holdings keeps its downside limited.
GLGC -rock bottom last month, now up, a little more expensive
ENZ still cheap.
AVII, NMPS, HEPH - all still cheap, having varying degrees of risk. NMPS low price makes no sense, given the technology they have. |
